Quest Diagnostics Incorporated $DGX Stake Boosted by Danske Bank A S

Danske Bank A S lifted its stake in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 24.6% during the third quarter, HoldingsChannel reports. The fund owned 85,461 shares of the medical research company’s stock after purchasing an additional 16,900 shares during the quarter. Danske Bank A S’s holdings in Quest Diagnostics were worth $19,918,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Next Level Wealth Planning LLC acquired a new stake in Quest Diagnostics during the third quarter valued at $25,000. Ancora Advisors LLC purchased a new position in Quest Diagnostics in the second quarter valued at about $29,000. Frazier Financial Advisors LLC acquired a new position in Quest Diagnostics in the 2nd quarter worth about $35,000. Ameritas Advisory Services LLC acquired a new position in Quest Diagnostics in the 2nd quarter worth about $45,000. Finally, Dunhill Financial LLC purchased a new stake in shares of Quest Diagnostics during the 2nd quarter worth about $46,000. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. JPMorgan Chase & Co. upped their price target on Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 28th. Weiss Ratings raised Quest Diagnostics from a “buy (a)” rating to a “buy (a+)” rating in a report on Wednesday, October 21st. Argus set a $260.00 price objective on Quest Diagnostics in a report on Wednesday, July 29th. Finally, UBS Group reissued a “neutral” rating and issued a $250.00 price objective on shares of Quest Diagnostics in a research note on Monday, October 19th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $248.70.

Read Our Latest Report on DGX

Key Stories Impacting Quest Diagnostics

Here are a few of the latest stories about DGX:

  • Positive Sentiment: Recent quarterly results provided support: Quest reported EPS of $3.00 and revenue of $3.10 billion, both above estimates, with revenue up 10% year over year.
  • Neutral Sentiment: Chief Accounting Officer Michael Deppe sold 11,776 shares for about $3.06 million, reducing his holding by 25.07%. The trade was made under a pre-arranged Rule 10b5-1 plan, which makes it less indicative of a sudden change in outlook. SEC filing
  • Negative Sentiment: Zacks Research lowered several future EPS forecasts, including Q1 2027 to $2.61 from $2.72, FY2027 to $11.69 from $11.73, and FY2028 to $12.77 from $12.90. The reductions are small but suggest slightly softer expectations for earnings growth. Q1 EPS estimates cut

Quest Diagnostics Price Performance

Shares of Quest Diagnostics stock opened at $261.67 on Tuesday. The company has a current ratio of 1.70, a quick ratio of 1.58 and a debt-to-equity ratio of 0.70. The firm has a fifty day simple moving average of $241.72 and a 200-day simple moving average of $215.98. The stock has a market capitalization of $28.79 billion, a price-to-earnings ratio of 23.52, a PEG ratio of 2.32 and a beta of 0.55. Quest Diagnostics Incorporated has a 1-year low of $171.18 and a 1-year high of $263.19.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.87 by $0.13. Quest Diagnostics had a net margin of 9.53% and a return on equity of 16.21%. The business had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period last year, the business posted $2.60 EPS. Quest Diagnostics’s revenue was up 10.0% compared to the same quarter last year. On average, sell-side analysts expect that Quest Diagnostics Incorporated will post 11.29 earnings per share for the current year.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 27th. Shareholders of record on Tuesday, January 12th will be given a dividend of $0.86 per share. The ex-dividend date of this dividend is Tuesday, January 12th. This represents a $3.44 dividend on an annualized basis and a yield of 1.3%. Quest Diagnostics’s payout ratio is currently 34.26%.

Insider Activity at Quest Diagnostics

In other news, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total value of $2,427,200.00. Following the transaction, the chief executive officer directly owned 122,423 shares in the company, valued at approximately $29,714,510.56. The trade was a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patrick Plewman sold 11,717 shares of Quest Diagnostics stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $257.34, for a total value of $3,015,252.78. Following the completion of the transaction, the senior vice president owned 14,684 shares in the company, valued at $3,778,780.56. The trade was a 44.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 79,478 shares of company stock valued at $19,794,031. 0.88% of the stock is owned by corporate insiders.

Quest Diagnostics Profile

(Free Report)

Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.

See Also

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.